Literature DB >> 15145327

The significance of the prepubertal diabetes duration for the development of retinopathy and nephropathy in patients with type 1 diabetes.

Birthe S Olsen1, Anne Katrin Sjølie, Philip Hougaard, Jesper Johannesen, Karin Marinelli, Bent Brock Jacobsen, Henrik B Mortensen.   

Abstract

OBJECTIVE: A Danish nationwide prospective cohort of children and adolescents with type 1 diabetes was followed for 8 years to study the effect of the prepubertal duration of diabetes on early retinopathy and elevated albumin excretion rate (AER) (>20 microg/min). RESEARCH DESIGN AND METHODS: In 1989, blood glucose control (HbA(1c)) and AER was investigated in approximately 80% of all Danish children and adolescents with type 1 diabetes. A cohort of 339 young patients were restudied in 1995 including physical examination, demographic data, HbA(1c), AER, and fundus photography with central reading. Among the patients, a number of 304 had a prepubertal onset of diabetes defined as an onset age less than 11.7 years in girls and 12.9 years in boys. Microalbuminuria was defined as an AER of 20-150 microg min(-1) and macroalbuminuria as AER >150 microg min(-1) in two out of three timed overnight urine samples.
RESULTS: At the follow-up in 1995-1996, no patients were younger than 12 years of age. The prevalence of any level of retinopathy was 17.7% in the age group 12-15 years, 45.4% from 16 to 20 years, and increased to 67.6% in patients more than 20 years of age. Diabetic retinopathy was significantly associated to poor long-term metabolic control (HbA(1c)) (P<.0001) and to diabetes duration both in patients with a prepubertal onset of disease as well as patients with a pubertal (P<.001) onset of disease. However, the pubertal diabetes duration contributed two times more than the prepubertal diabetes duration. Mean postpubertal diabetes duration to any retinopathy was significantly shorter (9.4 years) in patients with prepubertal onset of the disease compared to patients with postpubertal onset (11.8 years) (P=.0004). In total, the prevalence of elevated AER (>20 microg/min) increased from 4% in 1989 to 13% in 1995. None of the patients younger than 15 years of age had elevated AER, while the prevalence of elevated AER was about 14% from 15 years of age and onwards. Elevated AER in 1995 was significantly related to long-term metabolic control (P<.001) and elevated AER in the preceding years (P<.001) but was not correlated to diabetes duration neither before nor after the age of 12 years.
CONCLUSION: The prepubertal diabetes duration is significantly associated with the development of diabetic retinopathy. The period, however, contributes less compared to the years after puberty. In concert with other studies, we found no association between raised AER and diabetes duration. This may be explained by the fact that other factors are more significant and dilute the significance of diabetes duration. Nonetheless, it seems prudent to optimise blood glucose control irrespective of age.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15145327     DOI: 10.1016/S1056-8727(03)00073-4

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  32 in total

1.  Diabetic retinopathy in type 1 diabetes-a contemporary analysis of 8,784 patients.

Authors:  H P Hammes; W Kerner; S Hofer; O Kordonouri; K Raile; R W Holl
Journal:  Diabetologia       Date:  2011-06-03       Impact factor: 10.122

2.  Occurrence of microalbuminuria in young people with Type 1 diabetes: importance of age and diabetes duration.

Authors:  C R Alleyn; L K Volkening; J Wolfson; A Rodriguez-Ventura; J R Wood; L M B Laffel
Journal:  Diabet Med       Date:  2010-05       Impact factor: 4.359

3.  Screening eye exams in youth with type 1 diabetes under 18 years of age: Once may be enough?

Authors:  Rose A Gubitosi-Klug; Ionut Bebu; Neil H White; John Malone; Ryan Miller; Gayle M Lorenzi; Dean P Hainsworth; Victoria R Trapani; John M Lachin; William V Tamborlane
Journal:  Pediatr Diabetes       Date:  2019-07-09       Impact factor: 4.866

Review 4.  Nephropathy in youth and young adults with type 2 diabetes.

Authors:  Carolina Solis-Herrera; Curtis L Triplitt; Jane L Lynch
Journal:  Curr Diab Rep       Date:  2014-02       Impact factor: 4.810

5.  Effects of tamoxifen versus raloxifene on retinal capillary endothelial cell proliferation.

Authors:  Jeffery G Grigsby; Kalpana Parvathaneni; Miguel A Almanza; Angelica M Botello; Albert A Mondragon; Donald M Allen; Andrew T C Tsin
Journal:  J Ocul Pharmacol Ther       Date:  2011-03-17       Impact factor: 2.671

6.  Retinal vascular geometry and its association to microvascular complications in patients with type 1 diabetes: the Danish Cohort of Pediatric Diabetes 1987 (DCPD1987).

Authors:  M L Rasmussen; R Broe; U Frydkjaer-Olsen; B S Olsen; H B Mortensen; T Peto; J Grauslund
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-08-12       Impact factor: 3.117

7.  Kidney disease in childhood-onset diabetes.

Authors:  Robert G Nelson
Journal:  Am J Kidney Dis       Date:  2008-08-03       Impact factor: 8.860

8.  Cumulative risk, age at onset, and sex-specific differences for developing end-stage renal disease in young patients with type 1 diabetes: a nationwide population-based cohort study.

Authors:  Anna Möllsten; Maria Svensson; Ingeborg Waernbaum; Yonas Berhan; Staffan Schön; Lennarth Nyström; Hans J Arnqvist; Gisela Dahlquist
Journal:  Diabetes       Date:  2010-04-27       Impact factor: 9.461

Review 9.  Diabetic nephropathy in children and adolescents.

Authors:  Radovan Bogdanović
Journal:  Pediatr Nephrol       Date:  2007-10-17       Impact factor: 3.714

10.  Microaneurysm count as a predictor of long-term progression in diabetic retinopathy in young patients with type 1 diabetes: the Danish Cohort of Pediatric Diabetes 1987 (DCPD1987).

Authors:  M L Rasmussen; R Broe; U Frydkjaer-Olsen; B S Olsen; H B Mortensen; T Peto; J Grauslund
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-06-05       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.